Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...
Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis. This ...
Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...
Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...
The concept of skipping axillary lymph node dissection (ALND) in some patients with breast cancer was supported by a European noninferiority trial. Among patients with early-stage, node-negative ...
D. Scott Lind, M.D., F.A.C.S.; Barbara L. Smith, M.D., Ph.D., F.A.C.S.; Wiley W. Souba, M.D., Sc.D., F.A.C.S. Before the advent of SLN biopsy, axillary dissection was ...
Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment. Targeted axillary dissection is used for ...
Primary results of the BETTER-CARE trial: Implementation of a needs-adapted and individualized follow-up care after primary breast cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Annual ...
Please provide your email address to receive an email when new articles are posted on . Patients with breast cancer had similar survival whether they underwent completion axillary lymph node ...
Previous trials have shown that omission of axillary-lymph-node dissection does not appear to affect important outcomes. New research findings extend those findings and are summarized in a short video ...
Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results